OLFACTOMICS OY

Their core work

Olfactomics is a Finnish medical technology SME developing a real-time tissue analysis system for use during cancer surgery. Their core technology combines sensor arrays — likely detecting volatile organic compounds or chemical signatures from excised tissue — with AI to give surgeons instant feedback on whether surgical margins are clear of cancer cells. The primary application is breast-conserving surgery (lumpectomy), where the inability to assess margins intraoperatively currently drives re-operation rates of 20–30%. Their technology aims to eliminate that second surgery by delivering the equivalent of a rapid pathology result in the operating room.

What they specialise in

How they've shifted over time

Olfactomics entered H2020 in 2018 with a Phase 1 feasibility grant — a proof-of-concept exercise with no published keyword vocabulary, typical of a technology that had not yet been validated beyond the lab. By 2019, they had moved directly into a Phase 2 scale-up project, and a rich keyword set emerged: real-time analysis, sensor technology, AI, surgical tissue assessment, oncology, and lumpectomies — indicating rapid maturation from concept to clinical-stage development. The trajectory is linear and focused: there is no pivot, no diversification, just deepening execution of a single high-value application.

Olfactomics is moving from R&D toward commercialization of a surgical AI device — their next logical step is clinical trials, CE marking, and hospital adoption, making them a strong candidate for health-tech scale-up partnerships or medtech industry collaboration.

How they like to work

Olfactomics has functioned as a solo operator throughout their H2020 history — both projects were coordinated independently with no recorded consortium partners. This is consistent with the SME Instrument model, which is designed for single companies developing their own proprietary technology. It signals that they are a focused product company rather than a research network builder, and any future collaboration would likely be structured around technology licensing, clinical validation partnerships, or supply chain integration rather than joint research consortia.

Olfactomics has no recorded H2020 consortium partners and no international collaboration footprint in the available data. Their EU engagement has been exclusively through the SME Instrument, which does not require consortium building.

What sets them apart

Olfactomics occupies a precise and underserved niche: the moment between tissue excision and pathology report during cancer surgery. Very few companies globally are attacking the intraoperative margin assessment problem with a sensor-plus-AI approach, and Olfactomics has validated this concept through both Phase 1 and Phase 2 EU funding. For a consortium builder in surgical robotics, hospital digitalisation, or oncology diagnostics, Olfactomics brings a rare combination of clinical domain focus and a proprietary detection technology that is not replicated by conventional imaging or genomics players.

Highlights from their portfolio

• Olfactomics Surgery
  A €1.85M SME Phase 2 grant — among the largest available to a single SME — awarded to develop a full commercial-stage AI-powered intraoperative tissue analysis system for breast cancer surgery, validating both the technology and the market opportunity.
• Olfactomics
  The Phase 1 feasibility project that de-risked the core concept in 2018, directly enabling the Phase 2 award and demonstrating a clean technology maturation pathway within a single EU funding cycle.